CDA | Evidence Driven
CDA | Evidence Driven

Zykadia for Metastatic Non-Small Cell Lung Cancer - Details

Details

Files
Generic Name:
Ceritinib
Project Status:
Complete
Therapeutic Area:
Metastatic Non-Small Cell Lung Cancer
Manufacturer:
Novartis Pharmaceuticals Inc.
Brand Name:
Zykadia
Project Line:
Reimbursement Review
Project Number:
PC0062-000
Performance Metric:
Achieved
Strength:
150 mg capsule
Tumour Type:
Lung
Indications:
Metastatic Non-Small Cell Lung Cancer
Funding Request:
For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ceritinib (Zykadia) NSCLC - Final Recommendation Final Recommendation December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Final Clinical Guidance Report Guidance Reports December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Final Economic Guidance Report Guidance Reports December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Initial Recommendation Initial Recommendation October 1, 2015 View PDF
Ceritinib (Zykadia) NSCLC – PAG Feedback on Initial Recommendation Feedback December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Manufacturer Feedback on Initial Recommendation Feedback December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Patient Advocacy Group (LCC) Feedback on Initial Recommendation Feedback December 3, 2015 View PDF
Ceritinib (Zykadia) NSCLC – Patient Advocacy Group (LCC) COI Declarations COI Declarations December 3, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 18, 2015